Compositions and methods for enhancing immunity by chemoattractant adjuvants

• US 20070087986A1
• Filed: 07/31/2006
• Published: 04/19/2007
• Est. Priority Date: 01/26/2004
• Status: Abandoned Application

• Current Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Original Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Inventors: Schall, Thomas, Premack, Brett, Walters, Matthew
• Application Number:
  US11/496,267
• Publication Number:
  US 20070087986A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 39/07 Bacillus
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: C12N 2710/00088 for redistribution

Abstract

The invention is directed to methods and compositions for enhancing immunity, including mucosal immunity. The compositions include an antigen or immunogen, a ligand for a Toll-like receptor and at least one chemoattractant.

Claims

1. An immunogenic composition, comprising:

an antigen or immunogen;

at least one chemoattractant; and

a ligand for a Toll-like receptor (TLR).

2. The immunogenic composition of claim 1, wherein the ligand for TLR is a TLR9 ligand.

3. The immunogenic composition of claim 2, wherein the TLR9 ligand is CpG oligonucleotide.

4. The immunogenic composition of claim 1, wherein the chemoattractant is a chemokine or a w-peptide.

5. The immunogenic composition of claim 4, wherein the chemokine is selected from the group consisting of IL-8, GCP-2, Gro α

, Gro β

, Gro γ

, ENA-78, PBP, MIG, IP-10, I-TAC, SDF-1α

(PBSF), BLC (BCA-1), MIP-1α

, MIP-1β

, RANTES, HCC-1, -2, -3, and 4, MCP-1, -2, -3, and -4, eotaxin-1, eotaxin-2, TARC, MDC, MIP-3α

(LARC), MIP-3β

(ELC), 6Ckine (LC), I309, TECK, lymphotactin, fractalkine (neurotactin), TCA-4, Exodus-2, Exodus-3, and CKβ

-11.

6. The immunogenic composition of claim 4, wherein the ligand for TLR is a TLR9 ligand.

7. The immunogenic composition of claim 1, wherein the chemoattractant is a SHAAGtide polypeptide having at least 80% sequence identity to SEQ ID NO:

1.

8. The immunogenic composition of claim 7, wherein the ligand for TLR is a TLR9 ligand.

9. The immunogenic composition of claim 1, wherein the chemoattractant is a SHAAGtide polypeptide selected from the group consisting of SEQ ID NOS:

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11.

10. The immunogenic composition of claim 4, wherein the w-peptide is selected from the group consisting of SEQ ID NOS:

31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, and 58.

11. The immunogenic composition of claim 1, wherein the immunogenic composition is a vaccine composition.

12. The immunogenic composition of claim 1, wherein the antigen is a viral protein, polypeptide, or a fragment thereof;

a cancer or tumor antigen;

infectious disease agent;

a bacterial agent;

a parasite agent;

or a fungal agent.

13. The immunogenic composition of claim 1, wherein the composition induces mucosal immunity in a subject.

14. The immunogenic composition of claim 13, wherein the subject is a mammal.

15. The immunogenic composition of claim 13, wherein the subject is a human.

16. The immunogenic composition of claim 1, wherein the composition enhances an antibody response in a subject.

17. The immunogenic composition of claim 1, wherein the composition is for treatment of an infectious disease.

18. The immunogenic composition of claim 1, wherein the composition is for treatment of a cancer.

19. A method of enhancing immunity, comprising delivering to a subject an effective amount of a composition comprising an antigen, at least one chemoattractant, and a ligand for a Toll Like Receptor (TLR).

20. The method of claim 19, wherein the ligand for TLR is a TLR9 ligand.

21. The method of claim 19, wherein the method enhances mucosal immunity.

22. The method of claim 19, further comprising a step of measuring a level of immune response to the immunogenic composition, wherein the immune response is directed to the antigen or immunogen.

23. The method of claim 22, wherein the step of measuring comprises determining humoral response.

24. The method of claim 22, wherein the step of measuring comprises determining cell-mediated immune response.

25. A method for identifying an adjuvant compound that enhances immunity to an antigen or immunogen, comprising

delivering an immunogenic composition comprising the antigen or immunogen, at least one chemoattractant and a ligand for a Toll-like receptor to a subject;

and

measuring a level of immune response to the immunogenic composition, wherein the immune response is directed to the antigen or immunogen.

26. A method of inducing a mucosal immunity, comprising applying to a mucosal membrane in a subject an effective amount of a composition comprising an antigen or immunogen, at least one chemoattractant, and a CpG.

27. The method of claim 26, wherein the mucosal membrane is vaginal.

28. The method of claim 26, wherein the mucosal membrane is nasal.